Articles related to PHARMACOTHERAPY

Older adults with diabetes and frailty frequently experience overtreatment despite individualized glycemic goals that prioritize safety over intensive control. A narrative review highlights deprescribing strategies, relaxed glycemic targets, and medication adjustments intended to reduce hypoglycemia, falls, and treatment burden.

The FDA expanded the indication for olopatadine hydrochloride and mometasone furoate nasal spray to include children aged 6 to younger than 12 years with seasonal allergic rhinitis. Approval was supported by a phase 3 trial demonstrating improved nasal symptoms versus placebo.

Low-dose (Z)-endoxifen significantly reduced mammographic breast density in premenopausal women while producing fewer treatment-related symptoms than expected with standard tamoxifen exposure. The phase II findings suggest a potential new prevention strategy, but effects on actual breast cancer incidence remain unknown.

The FDA approved a low-estrogen weekly contraceptive patch for pregnancy prevention in eligible women with BMI below 30 kg/m². Approval was supported by Phase 3 efficacy, safety, and adhesion data, but use remains subject to established combined hormonal contraceptive contraindications.

The FDA approved Furoscix ReadyFlow, a subcutaneous furosemide autoinjector for edema associated with heart failure or chronic kidney disease. Clinical data demonstrated pharmacokinetic exposure and diuretic effects comparable to intravenous furosemide.

Retina practices are adjusting after Good Days funding limitations reduced copay support for some patients requiring chronic anti-VEGF therapy. Medicare Advantage patients appear especially exposed to affordability pressure.